Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 8/20 | 0.56 |
| ▸ | JAK1 | P23458 | 7/20 | 0.56 |
| ▸ | JAK2 | O60674 | 3/20 | 0.56 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | AKT1 | P31749 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3536209 | 1.00 | JAK3 (0.56) | JAK3JAK1JAK2IRAK4LRRK2 | |
| SCHEMBL3537467 | 0.79 | LRRK2 (0.67) | JAK3JAK1JAK2IRAK4LRRK2 | |
| SCHEMBL3539127 | 0.78 | STK4 (0.71) | JAK3JAK1JAK2LRRK2TP53 | |
| SCHEMBL3542500 | 0.77 | LRRK2 (0.58) | JAK3JAK1JAK2IRAK4LRRK2 | |
| SCHEMBL7087811 | 0.74 | STK4 (0.63) | JAK3JAK1JAK2LRRK2TP53 | |
| SCHEMBL3533457 | 0.72 | JAK3 (1.00) | JAK3JAK1JAK2 | |
| SCHEMBL3542483 | 0.72 | JAK3 (1.00) | JAK3JAK1JAK2 | |
| SCHEMBL3542178 | 0.72 | JAK3 (1.00) | JAK3JAK1JAK2 | |
| SCHEMBL3541754 | 0.72 | JAK3 (1.00) | JAK3JAK1JAK2 | |
| SCHEMBL3535221 | 0.72 | JAK3 (1.00) | JAK3JAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687507-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| US-6890929-B2 | Immunosuppressants; lupus, multiple sclerosis, skin disorders, antiarthritic agents, antihistamines, antiulcer agents, Crohn's disease | PFIZER, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1087970-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | PFIZER INC. | 2003-11-13 | — | — | US | disclosed |
| US-6610847-B2 | Tyrosine kinase inhibitors; immunosuppressants | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | JAK3 2/4885JAK1 1/4885JAK2 3/4885 |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK3, JAK1, JAK2 | JAK3 1/4885JAK1 2/4885JAK2 3/4885 |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | JAK1, JAK3, JAK2 | JAK3 2/4885JAK1 1/4885JAK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.